



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Whole Body Dual X-Ray Absorptiometry to Determine Body Composition

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 577

BCBSA Reference Number: 6.01.40
NCD/LCD: NA

Related Policies

- Bone Mineral Density Studies, #[450](#)
- Vertebral Fracture Assessment with Densitometry, #[449](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Dual x-ray absorptiometry (DXA) body composition studies are considered [INVESTIGATIONAL](#).

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is not a covered service.
Commercial PPO and Indemnity	This is not a covered service.
Medicare HMO Blue SM	This is not a covered service.
Medicare PPO Blue SM	This is not a covered service.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

CPT Codes

There is no specific CPT code for this service.

ICD Diagnosis Codes

Investigational for all diagnoses.

Description

Body Composition Measurement

Body composition measurements can be used to quantify and assess the relative proportions of specific body compartments such as fat and lean mass (eg, bones, tissues, organs, muscles). These measurements may be more useful in informing diagnosis, prognosis, or therapy than standard assessments (eg, body weight, body mass index) that do not identify the contributions of individual body compartments or their particular relationships with health and disease. While these body composition measurements have been most frequently utilized for research purposes, they may be useful in clinical settings to:

- Evaluate the health status of undernourished patients, those impacted by certain disease states (eg, anorexia nervosa, cachexia), or those undergoing certain treatments (eg, antiretroviral therapy, bariatric surgery).
- Evaluate the risk of heart disease or diabetes by measuring visceral fat vs total body fat.
- Assess body composition changes related to growth and development (eg, infancy, childhood), aging (eg, sarcopenia), and in certain disease states (eg, HIV, diabetes).
- Evaluate patients in situations where body mass index is suspected to be discordant with total fat mass (eg, body-building, edema).

A variety of techniques has been researched, including most commonly, anthropomorphic measures, bioelectrical impedance, and dual-energy x-ray absorptiometry (DXA). All of these techniques are based in part on assumptions about the distribution of different body compartments and their density, and all rely on formulas to convert the measured parameter into an estimate of body composition. Therefore, all techniques will introduce variation based on how the underlying assumptions and formulas apply to different populations of subjects (ie, different age groups, ethnicities, or underlying conditions). Techniques using anthropomorphics, bioelectrical impedance, underwater weighing, and DXA are briefly reviewed below.

Anthropomorphic Techniques

Anthropomorphic techniques for the estimation of body composition include measurements of skinfold thickness at various sites, bone dimensions, and limb circumference. These measurements are used in various equations to predict body density and body fat. Due to its ease of use, measurement of skinfold thickness is one of the most common techniques. The technique is based on the assumption that the subcutaneous adipose layer reflects total body fat but this association may vary with age and sex.

Bioelectrical Impedance

Bioelectrical impedance analysis is based on the relation among the volume of the conductor (ie, human body), the conductor's length (ie, height), the components of the conductor (ie, fat and fat-free mass), and its impedance. Estimates of body composition are based on the assumption that the overall conductivity of the human body is closely related to lean tissue. The impedance value is then combined with anthropomorphic data to give body compartment measures. The technique involves attaching surface

electrodes to various locations on the arm and foot. Alternatively, the patient can stand on the pad electrodes.

Underwater Weighing

Underwater weighing requires the use of a specially constructed tank in which the subject is seated on a suspended chair. The subject is then submerged in the water while exhaling. While valued as a research tool, weighing people underwater is typically not suitable for routine clinical use. This technique is based on the assumption the body can be divided into 2 compartments with constant densities: adipose tissue, with a density of 0.9 g/cm³, and lean body mass (ie, muscle and bone), with a density of 1.1 g/cm³. One limitation of the underlying assumption is the variability in density between muscle and bone; eg, bone has a higher density than muscle, and bone mineral density varies with age and other conditions. Also, the density of body fat may vary, depending on the relative components of its constituents (eg, glycerides, sterols, glycolipids).

Dual-energy X-ray Absorptiometry

While the cited techniques assume 2 body compartments, DXA can estimate 3 body compartments consisting of fat mass, lean body mass, and bone mass. DXA systems use a source that generates x-rays at 2 energies. The differential attenuation of the 2 energies is used to estimate the bone mineral content and soft tissue composition. When 2 x-ray energies are used, only 2 tissue compartments can be measured; therefore, soft tissue measurements (ie, fat and lean body mass) can only be measured in areas in which no bone is present. DXA can also determine body composition in defined regions (ie, the arms, legs, and trunk). DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%. Hydration, however, can vary from 67% to 85% and can vary by disease state. Other assumptions used to derive body composition estimates are considered proprietary by DXA manufacturers. The use of DXA for bone mineral density assessment in patients diagnosed with or at risk of osteoporosis is addressed separately in policy #450. Vertebral fracture assessment with densitometry by DXA is addressed separately in policy #449.

Summary

Description

Using low-dose x-rays of 2 different energy levels, whole-body dual-energy x-ray absorptiometry (DXA) measures lean tissue mass, total and regional body fat, as well as bone density. DXA scans have become a tool for research on body composition (eg, as a more convenient replacement for underwater weighing). This evidence review addresses potential applications in clinical care rather than research use of the technology.

Summary of Evidence

For individuals who have a clinical condition associated with abnormal body composition who receive DXA body composition studies, the evidence includes systematic reviews and several cross-sectional studies comparing DXA with other techniques. Relevant outcomes are symptoms and change in disease status. The available studies were primarily conducted in research settings and often used DXA body composition studies as a reference standard; these studies do not permit conclusions about the accuracy of DXA for measuring body composition. A systematic review exploring the clinical validity of DXA against reference methods for the quantification of intra-abdominal adipose tissue raised concerns regarding precision and reliability. More importantly, no studies were identified in which DXA body composition measurements were actively used in patient management. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a clinical condition managed by monitoring changes in body composition over time who receive serial DXA body composition studies, the evidence includes several prospective studies monitoring patients over time. Relevant outcomes are symptoms and change in disease status. The studies used DXA as a tool to measure body composition and were not designed to assess the accuracy of DXA. None of the studies used DXA findings to make patient management decisions or addressed how serial body composition assessment might improve health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy History

Date	Action
11/2020	BCBSA National medical policy review. Description, summary, and references updated. Policy statements unchanged.
10/2019	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
10/2018	BCBSA National medical policy review. Description, summary, and references updated. Policy statement unchanged.
1/2016	New references added from BCBSA National medical policy.
2/2016	BCBSA National medical policy review. Abbreviation in policy statement changed to DXA.
2/2015	New references added from BCBSA National medical policy.
3/2014	New references added from BCBSA National medical policy.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
12/2011	New policy describing ongoing non-coverage. Effective 12/2011.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Murphy J, Bacon SL, Morais JA, et al. Intra-Abdominal Adipose Tissue Quantification by Alternative Versus Reference Methods: A Systematic Review and Meta-Analysis. *Obesity (Silver Spring)*. Jul 2019; 27(7): 1115-1122. PMID 31131996
2. Sheean P, Gonzalez MC, Prado CM, et al. American Society for Parenteral and Enteral Nutrition Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations. *JPEN J Parenter Enteral Nutr*. Jan 2020; 44(1): 12-43. PMID 31216070
3. Calella P, Valerio G, Brodlie M, et al. Tools and Methods Used for the Assessment of Body Composition in Patients With Cystic Fibrosis: A Systematic Review. *Nutr Clin Pract*. Oct 2019; 34(5): 701-714. PMID 30729571
4. Calella P, Valerio G, Brodlie M, et al. Cystic fibrosis, body composition, and health outcomes: a systematic review. *Nutrition*. Nov 2018; 55-56: 131-139. PMID 29981489
5. Bundred J, Kamarajah SK, Roberts KJ. Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. *HPB (Oxford)*. Dec 2019; 21(12): 1603-1612. PMID 31266698
6. Alves FD, Souza GC, Biolo A, et al. Comparison of two bioelectrical impedance devices and dual-energy X-ray absorptiometry to evaluate body composition in heart failure. *J Hum Nutr Diet*. Dec 2014; 27(6): 632-8. PMID 24684316
7. Ziai S, Coriati A, Chabot K, et al. Agreement of bioelectric impedance analysis and dual-energy X-ray absorptiometry for body composition evaluation in adults with cystic fibrosis. *J Cyst Fibros*. Sep 2014; 13(5): 585-8. PMID 24522087
8. Elkan AC, Engvall IL, Tengstrand B, et al. Malnutrition in women with rheumatoid arthritis is not revealed by clinical anthropometrical measurements or nutritional evaluation tools. *Eur J Clin Nutr*. Oct 2008; 62(10): 1239-47. PMID 17637600
9. Jensky-Squires NE, Dieli-Conwright CM, Rossuello A, et al. Validity and reliability of body composition analysers in children and adults. *Br J Nutr*. Oct 2008; 100(4): 859-65. PMID 18346304
10. Kullberg J, Brandberg J, Angelhed JE, et al. Whole-body adipose tissue analysis: comparison of MRI, CT and dual energy X-ray absorptiometry. *Br J Radiol*. Feb 2009; 82(974): 123-30. PMID 19168691

11. Liem ET, De Lucia Rolfe E, L'Abée C, et al. Measuring abdominal adiposity in 6 to 7-year-old children. *Eur J Clin Nutr.* Jul 2009; 63(7): 835-41. PMID 19127281
12. Bedogni G, Agosti F, De Col A, et al. Comparison of dual-energy X-ray absorptiometry, air displacement plethysmography and bioelectrical impedance analysis for the assessment of body composition in morbidly obese women. *Eur J Clin Nutr.* Nov 2013; 67(11): 1129-32. PMID 24022260
13. Monteiro PA, Antunes Bde M, Silveira LS, et al. Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. *BMC Pediatr.* Jan 29 2014; 14: 25. PMID 24476029
14. Tompuri TT, Lakka TA, Hakulinen M, et al. Assessment of body composition by dual-energy X-ray absorptiometry, bioimpedance analysis and anthropometrics in children: the Physical Activity and Nutrition in Children study. *Clin Physiol Funct Imaging.* Jan 2015; 35(1): 21-33. PMID 24325400
15. Alves Junior CAS, de Lima LRA, de Souza MC, et al. Anthropometric measures associated with fat mass estimation in children and adolescents with HIV. *Appl Physiol Nutr Metab.* May 2019; 44(5): 493-498. PMID 30286302
16. Woolcott OO, Bergman RN. Defining cutoffs to diagnose obesity using the relative fat mass (RFM): Association with mortality in NHANES 1999-2014. *Int J Obes (Lond).* Jun 2020; 44(6): 1301-1310. PMID 31911664
17. Staunstrup LM, Nielsen HB, Pedersen BK, et al. Cancer risk in relation to body fat distribution, evaluated by DXA-scans, in postmenopausal women - the Prospective Epidemiological Risk Factor (PERF) study. *Sci Rep.* Mar 29 2019; 9(1): 5379. PMID 30926844
18. Reina D, Gomez-Vaquero C, Diaz-Torne C, et al. Assessment of nutritional status by dual X-Ray absorptiometry in women with rheumatoid arthritis: A case-control study. *Medicine (Baltimore).* Feb 2019; 98(6): e14361. PMID 30732168
19. Sinclair M, Hoermann R, Peterson A, et al. Use of Dual X-ray Absorptiometry in men with advanced cirrhosis to predict sarcopenia-associated mortality risk. *Liver Int.* Jun 2019; 39(6): 1089-1097. PMID 30746903
20. Lindqvist C, Brismar TB, Majeed A, et al. Assessment of muscle mass depletion in chronic liver disease: Dual-energy x-ray absorptiometry compared with computed tomography. *Nutrition.* May 2019; 61: 93-98. PMID 30703575
21. Dordevic AL, Bonham M, Ghasem-Zadeh A, et al. Reliability of Compartmental Body Composition Measures in Weight-Stable Adults Using GE iDXA: Implications for Research and Practice. *Nutrients.* Oct 12 2018; 10(10). PMID 30321991
22. Bazzocchi A, Ponti F, Cariani S, et al. Visceral fat and body composition changes in a female population after RYGBP: a two-year follow-up by DXA. *Obes Surg.* Mar 2015; 25(3): 443-51. PMID 25218013
23. Franzoni E, Ciccarese F, Di Pietro E, et al. Follow-up of bone mineral density and body composition in adolescents with restrictive anorexia nervosa: role of dual-energy X-ray absorptiometry. *Eur J Clin Nutr.* Feb 2014; 68(2): 247-52. PMID 24346474
24. Iyengar NM, Arthur R, Manson JE, et al. Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. *JAMA Oncol.* Feb 01 2019; 5(2): 155-163. PMID 30520976
25. Arthur RS, Xue X, Kamensky V, et al. The association between DXA-derived body fat measures and breast cancer risk among postmenopausal women in the Women's Health Initiative. *Cancer Med.* Feb 2020; 9(4): 1581-1599. PMID 31875358
26. American College of Radiology. ACR-SPR-SSR Practice Parameter for the Performance of Dual-energy X-ray Absorptiometry (DXA). 2018; <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/DXA.pdf>. Accessed August 6, 2020.
27. International Society for Clinical Densitometry. 2015 ISCD Official Positions - Adult. 2015; <https://www.iscd.org/official-positions/2015-iscd-official-positions-adult>. Accessed August 5, 2020.
28. International Society for Clinical Densitometry. 2019 ISCD Official Positions - Adult. 2019; <https://www.iscd.org/official-positions/2019-iscd-official-positions-adult>. Accessed August 7, 2020.
29. Dent E, Morley JE, Cruz-Jentoft AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. *J Nutr Health Aging.* 2018; 22(10): 1148-1161. PMID 30498820